WednesdayOct 25, 2017 2:57 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Seeks to Become A ‘Global Presence’

Sees opportunities for legalized marijuana marketing in Canada, Germany, all of Western Europe and South America Armed with $43 million in working capital, it sees advantages for itself in product and financing It has a proprietary process in its indoor growing environment to control temperature, humidity and water to produce standardized, pesticide-free cannabis ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) director Aaron Keay said in an interview with CannabisFN (CFN Media) that besides achieving greater market share in Canada, ABcann Global also sees opportunities for growth and presence in Western Europe, Germany and South America (http://dtn.fm/NIEj9). The company sells in…

Continue Reading

TuesdayOct 17, 2017 9:35 am

QualityStocksNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Names Paul Lucas as New Board Chair

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced its appointment of Paul Lucas as its new independent chair following founder Ken Clement’s decision to step down from the position. Clement will continue to serve as a member of the company’s board of directors. “Ken’s visionary leadership has given ABcann a great foundation to build upon and we appreciate his years of dedicated service and contributions,” Paul Lucas stated in the news release. “Having him maintain his position on the Board will help the Company maintain continuity of leadership and historical knowledge. I am thrilled to take on the…

Continue Reading

WednesdayOct 11, 2017 2:16 pm

QualityStocksNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Scales Up in Preparation for Canada’s Impending 2018 Recreational Cannabis Legalization

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) was one of the first companies to obtain a cannabis production license in Canada, and it continues going strong among the country’s limited number of licensed growers—only 62 to date. The company’s high-tech indoor growing environment—with every facet of the growing, curing and harvesting process controlled and monitored by computer—yields a high-quality product that is clean, steady and repeatable—something the company can effectively leverage should recreational cannabis legalization go through in 2018. An article discussing this reads: “Focused on scaling its operations and distinguishing itself through its proprietary organic and pesticide-free growing technology,…

Continue Reading

MondayOct 09, 2017 9:08 am

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Scaling Up to Meet Impending Spike in Cannabis Demand

Ever at the forefront of Canada’s cannabis market, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) was among the very first companies to obtain a cannabis production license in that country and has since been working to change the face of medical cannabis—both in Canada and globally. ABcann’s group of companies is working toward the aim of becoming the first cannabis pioneers to produce repeatable, standardized, plant-based medicines around the world. Every variable of ABcann’s cannabis growing, curing and harvesting process is computer-monitored and controlled. This high-tech indoor growing environment consistently yields a superior product that is clean, steady and repeatable—something…

Continue Reading

FridaySep 29, 2017 2:53 pm

QualityStocksNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Achieves $43M in Working Capital, Eyes Substantial Production Capacity Increase for 2018

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF), a manufacturer and distributor of medical cannabis in Canada, announced on August 29 (http://dtn.fm/Jx7vE) the achievement of working capital in the amount of $43 million from multiple financings, including strategic partnerships and private placements, during the six months ended June 30, 2017. During that period, ABcann recorded revenues of C$264,319, compared with $21,465 during the same period of 2016. For the six-month period ended June 30, the company’s revenues were $436,802, as compared with $21,840 for comparable period of the previous year. An article further discussing this reads: “ABcann’s first quarter as a…

Continue Reading

MondaySep 25, 2017 3:47 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Attains $43M in Capital, Plans Significant Production Capacity Increase

Aaron Keay, CEO, says plans set for greater production capacity and strategy for global distribution in emerging markets Expansion of ABcann’s Vanluven facility underway, along with construction of the company’s 150,000 sq. ft. Kimmett facility Napanee, Ontario-based firm uses proprietary plant-growing technology and is pursuing opportunities in Australia and Germany ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) achieved working capital of $43 million from multiple financings, including private placements and strategic partnerships, during the six months ended June 30, 2017, it announced on August 29 (http://dtn.fm/RHe5K). ABcann manufactures and distributes medical cannabis under a license issued by Health Canada to…

Continue Reading

TuesdaySep 19, 2017 3:34 pm

At ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), Medicinal Cannabinoid Quality and Safety are Founding Principles

Producer of consistent, standardized medicinal cannabis Menu of cannabis strains with varying CBD:THC ratios ABcann’s CBD-Med is one of Canada's highest-CBD products In an interview with Cantech Letter (http://dtn.fm/5Deu5), Aaron Keay, CEO of ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), talked about the factors that triggered the genesis of the company, one of Canada’s trailblazing producers of medicinal cannabis. Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available. Although, in general, not much of a bother to recreational users, to those using cannabis…

Continue Reading

MondaySep 18, 2017 10:23 am

QualityStocksNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Nets Total Proceeds of $11.9 Million from Exercise of Warrants

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced that it has received total proceeds of nearly $11.9 million from the exercise of an aggregate of 19,185,965 warrants since the closing of its acquisition of ABcann Medicinals Inc. on April 28, 2017. With these funds, ABcann’s current cash position stands at approximately $45 million, giving the company the means to execute previously outlined plans to expand its production capabilities. “ABcann thanks our shareholders for their continued support and confidence as we work toward expanding our facilities and increasing production,” Aaron Keay, director and CEO of ABcann, stated in the…

Continue Reading

FridaySep 15, 2017 1:34 pm

QualityStocksNewsBreaks – Recent Competitor Recalls Illustrate Importance of ABcann Global’s (TSX.V: ABCN) (OTCQB: ABCCF) Innovative, Pesticide-Free Cannabis Growth Practices

Recently, the Canadian government announced that Broken Coast Cannabis Ltd. was recalling several products sold in 2016 due to the discovery of two banned pesticides in random samples, and several other Canadian cannabis growers have also had product recalls this year after banned pesticides were discovered in their products during mandatory testing. Instances like these serve to further illustrate the importance of the controlled, pesticide-free medical marijuana growth practices of ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF), which continues to meet product demand through its Napanee, Ontario, production facility and is also moving forward with expansion plans. An article further…

Continue Reading

ThursdaySep 07, 2017 9:34 am

QualityStocksNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Names Barry Fishman as New CEO

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the appointment of Barry Fishman as its new chief executive officer, effective October 1, 2017. Fishman brings nearly two decades of experience as a business leader to the ABcann team, having most recently served as CEO of international specialty pharmaceutical company Merus Labs. Under his leadership, Merus’s sales and EBITDA grew at a CAGR of greater than 50 percent, leading to the company’s acquisition by Norgine B.V. in July 2017 for total considerations of roughly $342 million. “Barry's proven experience as a CEO of complex, highly-regulated organizations with international operations…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered